Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.
Suma Shah, MD
Advertisement
Assistant professor of neurology; director, MS and Neuroimmunology Fellowship Program, Duke Health
Articles by Suma Shah, MD
Advertisement
Latest Updated Articles
The Ever-Expanding Multiple Sclerosis TherapeuticsPublished: May 20th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
2
NRLP3 Inhibitor VTX3232 Well-Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
3
Rethinking Progressive MS Studies to Better Include Advanced Patients: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath
4
Targeting CD19+ B Cells With Inebilizumab in Myasthenia Gravis
5
